This Biotech Is Fighting a Silent Killer

And it has 60% upside... ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

BROUGHT TO YOU BY MANWARD PRESS Dealmaker's Diary: This Biotech Is Fighting a Silent Killer SPONSORED **URGENT AI BIOTECH EVENT** In the coming days, an AI biotech - currently trading for less than $10 - is expected to make a bombshell announcement. And I do mean BOMBSHELL. These announcements have historically been known to generate FAR more explosive gains than FDA approval... and in a MUCH shorter time... As much as 509% MORE gains in some cases. Companies that have made similar announcements have seen their shares positively SOAR. And on June 27 at 2 p.m. ET, America's #1 stock catalyst expert wants to give you all the details. Including why this coming announcement could be bigger and more important than anything we've seen in a lifetime. Claim a free spot to attend right here.   Alpesh Patel Quantitative Investing Specialist Chronic and life-threatening diseases are on the rise... But one company stands tall in the fight against a silent killer: pulmonary arterial hypertension. It's a $12 billion biotech with a track record of impressive run-ups. And when I put it through my proprietary Value-Growth-Income algorithm... the results are stunning. SPONSORED 4,735% Revenue Surge: The Linchpin of Nvidia's AI Dominance? As Nvidia's new Blackwell chip sparks an AI revolution, one company is poised to skyrocket. This unsung hero's revenue could soar up to 4,735% in the next 12 months as tech titans line up to secure their groundbreaking technology. Early investors could see life-changing gains as this story unfolds. Don't miss your chance to ride the AI mega-trend.   A score of 9 out of 10. A forecast P/E ratio of just 11.5. And a cash return on capital invested of 12%. In a sector known for volatility, this stock is a rare beacon of stability. Plus... it has a potential upside of 60% based on its discount cash flow valuation. Don't miss out on the potential of this biotech gem. Get all the details on the company - including the ticker - in my latest video. Click here or on the image below to watch it. WATCH THE VIDEO (WITH TRANSCRIPT) Happy hunting, Alpesh SPONSORED Alexander Green's 3-Minute Stock Secret Join investment titan Alexander Green as he unveils the simple yet powerful technique that helped him find Netflix before it soared 43,000% since 2005. Find out what it is right here.   Want more content like this? YES NO

Alpesh Patel Alpesh Patel is an award-winning hedge fund and private equity fund manager, international bestselling author, and entrepreneur. He is the founder and CEO of Praefinium Partners, a Financial Times top FTSE 100 forecaster, and a senior Dealmaker in the U.K.'s Department for International Trade. As a recognized authority on fintech, online trading and venture capital, his past and current client list includes American Express, Merrill Lynch HSBC, Charles Schwab, Goldman Sachs, Barclays... and more.

You are receiving this email because you subscribed to Total Wealth. To unsubscribe from Total Wealth, click here. Need help with your account? Click here. Have a question or comment for the editor? Click here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Manward Press | Attn: Member Services | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 1.800.682.5210 | International: +1.443.353.4263 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Total Wealth. © 2024 Manward Press, LLC | All Rights Reserved

Nothing published by Manward Press, LLC should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Manward Press, LLC should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Manward Press, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.